Imunon Inc Total Liabilities
Imunon Inc total liabilities. Based on the latest financial reports, Imunon Inc (IMNN) has total liabilities worth $10.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IMNN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Imunon Inc (1996–2025)
Total liabilities of Imunon Inc from 1996 to 2025. This chart illustrates how Imunon Inc's total liabilities have evolved over time, based on quarterly financial data. Explore IMNN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Imunon Inc Competitors by Total Liabilities
The table below lists competitors of Imunon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aqua Metals Inc
NASDAQ:AQMS
|
USA | $3.09 Million |
|
Gaming Factory S.A.
WAR:GIF
|
Poland | zł5.85 Million |
|
Arrive AI Inc.
NASDAQ:ARAI
|
USA | $12.87 Million |
|
TruCap Finance Limited
NSE:TRU
|
India | Rs3.42 Billion |
|
Labat Africa Ltd
JSE:LAB
|
South Africa | ZAC456.03 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
UK | GBX3.69 Million |
|
Alchemy Resources Ltd
AU:ALY
|
Australia | AU$348.40K |
|
Goodbye Kansas Group AB (publ)
ST:GBK
|
Sweden | Skr80.31 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Imunon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMNN total asset value.
Liquidity & Leverage Metrics
Imunon Inc Total Liabilities Ratios Explained
Imunon Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imunon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imunon Inc (1996–2025)
The table below shows the annual total liabilities of Imunon Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.23 Million | -4.51% |
| 2024-12-31 | $5.47 Million | -35.84% |
| 2023-12-31 | $8.53 Million | -41.76% |
| 2022-12-31 | $14.65 Million | -19.74% |
| 2021-12-31 | $18.25 Million | -3.52% |
| 2020-12-31 | $18.92 Million | -20.25% |
| 2019-12-31 | $23.72 Million | -8.75% |
| 2018-12-31 | $25.99 Million | +24.91% |
| 2017-12-31 | $20.81 Million | -13.74% |
| 2016-12-31 | $24.12 Million | -15.78% |
| 2015-12-31 | $28.64 Million | -15.43% |
| 2014-12-31 | $33.87 Million | +139.41% |
| 2013-12-31 | $14.15 Million | +5.60% |
| 2012-12-31 | $13.40 Million | +107.52% |
| 2011-12-31 | $6.46 Million | -9.08% |
| 2010-12-31 | $7.10 Million | +48.88% |
| 2009-12-31 | $4.77 Million | +20.39% |
| 2008-12-31 | $3.96 Million | -52.77% |
| 2007-12-31 | $8.39 Million | -62.10% |
| 2006-12-31 | $22.13 Million | +77.27% |
| 2005-12-31 | $12.48 Million | +145.70% |
| 2004-12-31 | $5.08 Million | +414.88% |
| 2003-12-31 | $986.84K | +27.34% |
| 2002-12-31 | $774.96K | +169.42% |
| 2001-12-31 | $287.64K | -26.51% |
| 2000-12-31 | $391.39K | -34.77% |
| 1999-12-31 | $600.00K | -72.50% |
| 1998-12-31 | $2.18 Million | -33.56% |
| 1997-12-31 | $3.28 Million | +27.99% |
| 1996-12-31 | $2.57 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more